EOLS
Evolus, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$9.30
+2.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 316.5M | 297.2M | 266.3M | 202.1M | 148.6M |
| Cost of Revenue | 106.8M | 104.4M | 84.0M | 61.6M | 58.8M |
| Gross Profit | 209.7M | 192.8M | 182.3M | 140.5M | 89.8M |
| Operating Expenses | |||||
| R&D Expense | 9.7M | 9.6M | 9.2M | 15.4M | 6.7M |
| SG&A Expense | 216.5M | 220.8M | 198.0M | 164.9M | 141.8M |
| General & Admin Expense | — | — | 189.3M | 157.5M | 130.2M |
| Selling & Marketing Expense | — | — | 8.7M | 7.5M | 11.6M |
| Other Expenses | 6.7M | — | 9.5M | 9.4M | 6.5M |
| Total Operating Expenses | 232.9M | 230.4M | 216.7M | 189.8M | 155.1M |
| Cost and Expenses | 339.7M | 334.8M | 300.7M | 251.3M | 213.9M |
| Operating Income (EBIT) | (23.2M) | (37.6M) | (34.4M) | (49.2M) | (65.3M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 1.9M | 3.3M | 860.0K | 119.0K |
| Interest Expense | 16.2M | 19.7M | 18.7M | 13.8M | 9.1M |
| Net Interest Income | (14.9M) | (17.8M) | (15.5M) | (13.0M) | (9.0M) |
| Other Non-Op Income/Expense | (10.5M) | (13.4M) | (15.3M) | (12.3M) | (9.0M) |
| Non-Operating Income (excl Interest) | (5.7M) | (6.3M) | (3.4M) | (1.6M) | (7.8M) |
| EBT (Pre-Tax Income) | (33.7M) | (51.0M) | (49.8M) | (61.5M) | (74.3M) |
| Income Tax Expense | 654.0K | 677.0K | 664.0K | 176.0K | 95.0K |
| Bottom Line | |||||
| Net Income | (34.3M) | (51.6M) | (50.4M) | (61.7M) | (74.4M) |
| Earnings from Cont. Ops | (34.3M) | (51.6M) | (50.4M) | (61.7M) | (74.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (34.3M) | (51.6M) | (50.4M) | (61.7M) | (74.4M) |
| Per Share | |||||
| Basic EPS | ($0.52) | ($0.80) | ($0.81) | ($1.08) | ($1.33) |
| Diluted EPS | ($0.52) | ($0.80) | ($0.81) | ($1.08) | ($1.33) |
| Revenue Per Share | $4.80 | $4.61 | $4.29 | $3.55 | $2.65 |
| Shares | |||||
| Basic Shares Outstanding | 65.9M | 64.5M | 62.0M | 56.9M | 56.1M |
| Diluted Shares Outstanding | 65.9M | 64.5M | 62.0M | 56.9M | 56.1M |
| Profitability Metrics | |||||
| EBITDA | (10.2M) | (22.5M) | (25.0M) | (41.8M) | (53.9M) |
| D&A | 7.2M | 8.7M | 6.0M | 5.9M | 3.7M |
| EBIT | (17.5M) | (31.3M) | (31.0M) | (47.7M) | (57.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026